Prefer L&T, SBI, Aurobindo Pharma: Shahina Mukadam

Shahina Mukadam, Independent Market Expert is of the view that one may prefer Larsen and Toubro, State Bank of India and Aurobindo Pharma.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney IThe Winning Leap Tech Control

Budget 2017

Presented By:

DAYS hours minutes
Presented by :

Co-Presenting Sponsor :

Associate Sponsors :

Co-Presenting Sponsor :

Associate Sponsors :

Home » News » Stocks Views

Sponsored by :

Jan 11, 2017, 03.40 PM | Source: CNBC-TV18

Prefer L&T, SBI, Aurobindo Pharma: Shahina Mukadam

Shahina Mukadam, Independent Market Expert is of the view that one may prefer Larsen and Toubro, State Bank of India and Aurobindo Pharma.

Like this story, share it with millions of investors on M3

Prefer L&T, SBI, Aurobindo Pharma: Shahina Mukadam

Shahina Mukadam, Independent Market Expert is of the view that one may prefer Larsen and Toubro, State Bank of India and Aurobindo Pharma.

Post Your Comments

Share Cancel

| 1 Comments

Shahina Mukadam (more)

, | Capital Expertise: Equity - Fundamental

Shahina Mukadam, Independent Market Expert told CNBC-TV18, " Larsen and Toubro (L&T) has not shown any performance in the last one year odd, but I think now the momentum seems to be coming back. The last quarter numbers were pretty steady. I expect similar performance in the current quarter. Also since the base is much lower last year I think December quarter number should look pretty health."

"As we have seen while there could be some order book could take some more time to really pick up momentum, but I think the cost optimisation that the company has put in place should enable it to improves its margin."

"Second one would be another long-term relatively stable stock like State Bank of India (SBI). There again, we are likely to see a decent of numbers; treasury gains should boost the profitability for the bank in this quarter. Also I think going forward with interest rates coming down, it will be able to maintain its market share. That is one bank which should continue to do well in the PSU space."

"I would prefer  Aurobindo Pharma . I personally hold the stock. Here it is a combination of the potential over the next two to three years where they have got a statin product which will be a relative less competition product that will be launched in a US market. That should drive revenues in the next year. As well as valuations are there in its advantage, so I think Aurobindo Pharma could be another stock that one could look at," she added.
Buy, Hold, Sell ? Hear it first on M3
Prefer L&T, SBI, Aurobindo Pharma: Shahina Mukadam

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login